Literature DB >> 19816686

[The initial CUP situation and CUP syndrome: pathological diagnostics].

R Moll1.   

Abstract

"Cancer of unknown primary (site)" (CUP) represents a frequent and often difficult task for diagnostic histopathology. In the initial CUP situation, immunohistochemistry, which is relatively cost-efficient and non-burdensome for the patient, contributes substantially to the targeted search for and identification of the primary tumor. It may be performed in a two-step algorithm (keratins as the first step, group and selective markers as the second step). However, in true CUP syndrome--a heterogeneous disease whose etiology and pathogenesis is still poorly understood--the primary tumor is rarely identified, and the immunohistochemical marker profile is often anomalous. Nevertheless, immunohistochemistry remains the most important special method, aiming at the phenotypical classification and particularly the identification of certain favorable therapy-responsive subsets. Novel methods for subtyping of CUP based on the analysis of gene expression profiles need to be further evaluated before their possible diagnostic application. Future basic and clinical research is required to unravel the still enigmatic tumor biology of the CUP syndrome and to improve the hitherto very unfavorable prognosis by developing new efficient therapy regimens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19816686     DOI: 10.1007/s00292-009-1193-5

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  27 in total

Review 1.  Cancer from an unknown primary site.

Authors:  Jonathan E Dowell
Journal:  Am J Med Sci       Date:  2003-07       Impact factor: 2.378

2.  Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas.

Authors:  O Kaufmann; J Volmerig; M Dietel
Journal:  Am J Clin Pathol       Date:  2000-05       Impact factor: 2.493

3.  An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.

Authors:  Richard W Tothill; Adam Kowalczyk; Danny Rischin; Alex Bousioutas; Izhak Haviv; Ryan K van Laar; Paul M Waring; John Zalcberg; Robyn Ward; Andrew V Biankin; Robert L Sutherland; Susan M Henshall; Kwun Fong; Jonathan R Pollack; David D L Bowtell; Andrew J Holloway
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

4.  Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies.

Authors:  R Moll; A Löwe; J Laufer; W W Franke
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

5.  [CUP syndrome: molecular pathogenesis and biology].

Authors:  A Krämer; S Gattenlöhner; K Neben
Journal:  Pathologe       Date:  2009-03       Impact factor: 1.011

6.  [Immunohistochemical diagnosis in cancer metastasis of unknown primary tumor].

Authors:  O Kaufmann; E Fietze; M Dietel
Journal:  Pathologe       Date:  2002-05       Impact factor: 1.011

7.  Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors.

Authors:  Amitabh Srivastava; Jason L Hornick
Journal:  Am J Surg Pathol       Date:  2009-04       Impact factor: 6.394

Review 8.  Diagnostic and therapeutic management of cancer of an unknown primary.

Authors:  N Pavlidis; E Briasoulis; J Hainsworth; F A Greco
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

9.  Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas.

Authors:  Douglas C Parker; Andrew L Folpe; Julie Bell; Esther Oliva; Robert H Young; Cynthia Cohen; Mahul B Amin
Journal:  Am J Surg Pathol       Date:  2003-01       Impact factor: 6.394

10.  Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas.

Authors:  R Moll; X R Wu; J H Lin; T T Sun
Journal:  Am J Pathol       Date:  1995-11       Impact factor: 4.307

View more
  3 in total

1.  CUP Syndrome in Neuroendocrine Neoplasia: Analysis of Risk Factors and Impact of Surgical Intervention.

Authors:  Nehara Begum; Ulrich Wellner; Christoph Thorns; Georg Brabant; Martin Hoffmann; Conny Georg Bürk; Hendrik Lehnert; Tobias Keck
Journal:  World J Surg       Date:  2015-06       Impact factor: 3.352

2.  Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases.

Authors:  Nicole Posorski; Daniel Kaemmerer; Guenther Ernst; Patricia Grabowski; Dieter Hoersch; Merten Hommann; Ferdinand von Eggeling
Journal:  Clin Exp Metastasis       Date:  2011-06-17       Impact factor: 5.150

3.  Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling.

Authors:  Carmen Binder; Katarina Luise Matthes; Dimitri Korol; Sabine Rohrmann; Holger Moch
Journal:  Cancer Med       Date:  2018-07-17       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.